SOURCE: Skystar Bio-Pharmaceutical

November 12, 2010 14:30 ET

Skystar to Present at Upcoming Investor Conferences

XI'AN, CHINA--(Marketwire - November 12, 2010) -  Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced the Company will present at two upcoming institutional investor conferences in New York City: Brean Murray, Carret & Co. 2010 China Growth Conference and Maxim Group's 2010 Growth Conference.

Scott Cramer, Skystar's Director and U.S. representative, and Michael Lan, Skystar's Chief Financial Officer, will lead the investor presentations and one on one meetings at these upcoming conferences.

Brean Murray, Carret & Co. 2010 China Growth Conference

Skystar's group investor presentation at Brean Murray, Carret & Co. China Growth Conference will be held on Wednesday, November 17 at 10:00am (EST). The conference will be held at the Millennium Broadway Hotel in New York City.

Maxim Group Growth Conference 2010

Skystar's group presentation at the Maxim Group Growth Conference will be on Thursday, November 18, 2010 at 8:30 AM (EST). The conference will be held at the Grand Hyatt in New York City.

Interested parties and institutional investors who wish to meet with Skystar Bio-Pharmaceutical's representatives at these conferences may contact Brean Murray, Carret & Co. and Maxim Group directly.

To be added to the Company's email distribution for future news releases, please send your request to

About Skystar Bio-Pharmaceutical Company
Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 240 products. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit

Contact Information

  • Contacts:
    Skystar Bio-Pharmaceutical Company
    Scott Cramer, Director Corporate Development and U.S. Representative
    (407) 645-4433

    Investor Relations
    Christopher Chu
    (646) 284-9426